Anzeige
Mehr »
Mittwoch, 22.04.2026 - Börsentäglich über 12.000 News
Diese Aktie zündet die nächste Explorationsstufe - und der Markt beginnt aufzuwachen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A403UF | ISIN: SE0022049920 | Ticker-Symbol: LS60
Frankfurt
22.04.26 | 08:10
0,390 Euro
+0,39 % +0,002
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CLINICAL LASERTHERMIA SYSTEMS AB Chart 1 Jahr
5-Tage-Chart
CLINICAL LASERTHERMIA SYSTEMS AB 5-Tage-Chart

Aktuelle News zur CLINICAL LASERTHERMIA SYSTEMS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CLINICAL LASERTHERMIA SYSTEMS Aktie jetzt für 0€ handeln
20.02.Clinical Laserthermia Systems AB: Clinical Laserthermia Systems AB publishes Year-end report January - December 2025234Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today publishes its Year-end report for January - December 2025.Highlights of the Year-end report 2025The year 2025 represents...
► Artikel lesen
08.01.Clinical Laserthermia Systems AB: TRANBERG Thermal Therapy System installed at Andros Clinics for Launch of Ultrasound-Guided Focal Laser Ablation Program in The Netherlands1
12.12.25Clinical Laserthermia Systems AB: CLS initiates recruitment process for permanent Chief Financial Officer213Clinical Laserthermia Systems AB (publ) ("CLS") today announces that the company has decided to transition from its current interim, part-time consulting CFO arrangement to a permanent and fully employed...
► Artikel lesen
03.12.25Clinical Laserthermia Systems Submits CE-Marking Application for its ClearPoint Prismbranded Neuro Laser Therapy System seeking European Regulatory Approval for use in Neurosurgery1
14.11.25Clinical Laserthermia Systems AB: CLS Publishes Interim Report January - September 2025925Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today publishes its interim report for January - September 2025.Highlights of the Third Quarter Interim ReportDuring the...
► Artikel lesen
07.10.25Clinical Laserthermia Systems AB: CLS-sponsored neuro LITT study in patients with malignant brain tumor shows positive results182Lund, Sweden, October 7th, 2025 - Clinical Laserthermia Systems AB (publ) ("CLS") today announces positive results from a clinical safety study on laser ablation, performed using CLS proprietary LITT...
► Artikel lesen
04.09.25Clinical Laserthermia Systems AB: Clinical Laserthermia Systems Receives FDA Clearance for Expanded Labeling of the ClearPoint Prism[] Neuro Laser Therapy System, doubling the addressable U.S market for Neuro LITT322Lund, Sweden - September 4th, 2025 - Clinical Laserthermia Systems AB (publ) ("CLS" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for expansion...
► Artikel lesen
22.08.25Clinical Laserthermia Systems AB: CLS publishes half-year report January - June 2025310Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today publishes its half year report January - June 2025. Second Quarter Highlights Record sales revenue of SEK 9,4M...
► Artikel lesen
16.05.25Clinical Laserthermia Systems AB: Clinical Laserthermia Systems AB publishes Interim report for January - March 2025282Summary of the interim report (relates to the Group)Three months (01/01/2025-03/31/2025) Net sales totaled SEK 4,496,000 (SEK 3,140,000). Operating profit totaled SEK -7,868,000 (SEK -16,992,000). Profit/loss...
► Artikel lesen
28.04.25ClearPoint Neuro, Inc.: ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism to Include 1.5 T MRI271SOLANA BEACH, CA / ACCESS Newswire / April 28, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the...
► Artikel lesen
10 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1